The volatility continues in Inovovio Pharmaceuticals (INO) today, with the stock rising over 32% on no significant news
Dear seeking alpha,
While some of the recent price rise the last few weeks was due to speculation of partnership. Inovio has released plenty of significant news as of late. You guys continue to publish your short articles with the questionable timing. On the flip side you release a article saying INO could be merck's solution. Thanks for your market games and continued manipulation. Now the fact is a big pharma partnership has been INO's goal for sometime. The CEO speaking in June told investors he expects a partnership in the next few months. The real title of your article should be due to naked shorting and continued spread of misinformation my media sources ino's stock has moved down for no apparent reason.
These significant news releases over the first half of year might have something to with the over all higher share price.
Jan 7, 2013
PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner to Accelerate Development of Malaria Vaccines and Innovative Delivery Technologies
Jan 9, 2013
Inovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
Apr 10, 2013
Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Apr 18, 2013
Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
Apr 18, 2013
Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
May 14, 2013
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
Jun 14, 2013
Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
Jul 8, 2013
Inovio Pharmaceuticals' Universal H7N9 DNA Vaccine Protects 100% of Vaccinated Animals in Challenge Study
Jul 10, 2013
Inovio's CELLECTRA® Electroporation Delivery Technology Powers Durable, Best-in-Class T-Cell Responses from HIV Vaccine in Human Study
Jul 18, 2013
Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovio's Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
Jul 24, 2013
Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
Aug 15, 2013
Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
(not to mention the 7 conferences their attending in September)
AI
